Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Hold" from AnalystsMarket Beat·22 hours agoANNX-0.20%BLK+1.39%
Annexin Pharmaceuticals Q2 FY26 net loss widens to SEK 11.56 million; operating loss deepens to SEK 11.56 millionPUBT·Aug 21 at 01:33 AMANNX-0.20%
Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patientsPUBT·Aug 21 at 01:05 AMANNX-0.20%
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on TrackTradingKey·Aug 17 at 03:02 AMANNX-0.20%
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's ChangedSimplywall·Aug 14 at 02:32 AMANNX-0.20%
Annexon files Form 3 as director Mark S. Blumenkranz reports no beneficial ownershipPUBT·Aug 12 at 05:09 PMANNX-0.20%
Annexon: Strategic Phase 3 Trial Flexibility Supports Buy Rating and Unchanged $25 Price TargetTip Ranks·Aug 12 at 10:55 AMANNX-0.20%
Annexon (NASDAQ:ANNX) Shares Gap Down on Disappointing EarningsMarket Beat·Aug 12 at 09:20 AMANNX-0.20%
